VEGFA and nonpapillary renal cell carcinoma: Angiogenesis is essential for tumor growth and metastasis, thus VEGF, the most potent mediator of vessel formation [12], is the final target of TKIs which are used for treatment of ccRCC such as sunitinib, sorafenib, axitinib and pazopanib.